TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17606475
Drug: Lorazepam (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1.5 mg)
Study: 26120988
Drug: Vasonit and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasonit and standard treatment
Study: 20530296
Drug: Current levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current levels of augmentation index
Study: 18411833
Drug: Asthma psychoeducation
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asthma psychoeducation program with family therapy
Study: 10714568
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy consisting of stavudine + lamivudine + nelfinavir + saquinavir for 26 weeks
Study: 2836204
Drug: Controlled-release metoprolol
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release metoprolol 100 mg
Study: 2836204
Drug: Controlled-release metoprolol
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release metoprolol 200 mg
Study: 29117643
Drug: Coated activated
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated activated charcoal haemoperfusion (CAC‐HP) plus standard care (oral activated charcoal)
Study: 29117643
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (oral activated charcoal)
Study: 24318788
Drug: Neuromuscular training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular training (20‐min warm‐up program performed twice weekly for 10 weeks)
Study: 15328673
Drug: Fexofenadine hydrochloride
Normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine hydrochloride (20, 60, 120, or 240 mg twice daily)
Study: 22369270
Drug: Corticosteroids treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids treatment
Study: 8401048
Drug: Terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 1% cream applied twice daily for one week
Study: 8401048
Drug: Clotrimazole 1%
Normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole 1% cream applied twice daily for four weeks
Study: 3780287
Drug: Prophylactic salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic salbutamol (200 micrograms 4-times daily)
Study: 3780287
Drug: Symptomatic placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic placebo inhaler (2 actuations 4-times daily)
Study: 19875685
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg oral for 7 days)
Study: 11089515
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg rizatriptan
Study: 9358715
Drug: Both programs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both programs with nicotine-replacement therapy
Study: 2939542
Drug: Placebo (discography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (discography followed by injection of distilled water)
Study: 31604088
Drug: Intramuscular triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular triamcinolone
Study: 25974640
Drug: LY2963016 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2963016 insulin glargine
Study: 25974640
Drug: Lantus® insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lantus® insulin glargine
Study: 19589522
Drug: Minimal stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal stimulation using recombinant human FSH (rhFSH) and GnRH antagonist
Study: 19589522
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist multiple-dose protocol (MDP)
Study: 16310924
Drug: BXL628 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BXL628 150 mcg daily
Study: 2844338
Drug: Intravenous cytomegalovirus
Normalized name: cytomegalovirus immunoglobulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cytomegalovirus immune globulin
Study: 2844338
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no intravenous cytomegalovirus immune globulin)
Study: 29742109
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (tolterodine 1 mg)
Study: 25413975
Drug: Phototherapy (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phototherapy (combination of super-pulsed laser and light-emitting diodes)
Study: 23428336
Drug: L-Acetylcarnitine (LAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Acetylcarnitine (LAC) plus placebo
Study: 23428336
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/die plus placebo
Study: 18438230
Drug: W+B (water
Approvals — FDA: no, EMA: no, PMDA: no
Description: W+B (water + 5 g x L(‐1) betaine)
Study: 18438230
Drug: C+B (6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+B (6% carbohydrate-electrolyte fluid + 5 g x L(‐1) betaine)
Study: 16937274
Drug: Once-weekly 17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly 17.5 mg risedronate
Study: 16937274
Drug: Once-daily 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily 2.5 mg risedronate
Study: 11128859
Drug: 38 mg
Normalized name: alloin 38 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38 mg x kg(‐1) x d(‐1) of HMB
Study: 11128859
Drug: 76 mg
Normalized name: menthol 76 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 76 mg x kg(‐1) x d(‐1) of HMB
Study: 11128859
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg x kg(‐1) x d(‐1) (Control)
Study: 8077790
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (well hydrated with cristalloid saline solution)
Study: 795379
Drug: Fluocinonide gel
Normalized name: Fluocinonide Gel
DrugBank: Fluocinonide (DB01047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinonide gel
Study: 795379
Drug: Betamethasone benzoate
Normalized name: Betamethasone Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone benzoate gel
Study: 29149146
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg with bupivacaine 0.25%
Study: 25142189
Drug: Palifermin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palifermin (60 μg/kg IV for 3 days before and after chemotherapy)
Study: 19614803
Drug: Candesartan (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (32 mg) + Aspirin (300 mg/d)
Study: 9660521
Drug: Barnidipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barnidipine (10 mg) once daily
Study: 9660521
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 mg) once daily
Study: 2039655
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg Aminophylline
Study: 22097175
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment after regression of proteinuria (Group B)
Study: 16982486
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate (15 mg of zinc) once daily for prophylaxis, increased to 30 mg at onset of cold
Study: 10649149
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol plus norethindrone acetate (50 microg/d estradiol + 140/250/400 microg/d norethindrone acetate)
Study: 1341607
Drug: Pulsatile insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile insulin delivery (1.0 mU/kg x min in 2 minute pulses every 13 minutes)
Study: 1341607
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin delivery (0.15 mU/kg x min)
Study: 1341607
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin delivery (0.20 mU/kg x min)
Study: 6130244
Drug: More intensive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More intensive management program (group A) using ultralente insulin as basal cover and soluble insulin at mealtimes, with more frequent clinic visits, closer dietary supervision, and home blood glucose monitoring
Study: 1771386
Drug: Magaldrate (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magaldrate (800 mg every 4 h)
Study: 29500454
Drug: sacubitril/valsartan (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan (400 mg QD)
Study: 29500454
Drug: amlodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine (10 mg QD)
Study: 24777959
Drug: Topical menthol
Normalized name: menthol Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical menthol application
Study: 23463651
Drug: Combination training
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination training (ATRT)
Study: 18580879
Drug: Domperidone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (0.3 mg/kg per os at the eighth and sixteenth hour)
Study: 8707471
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (stressed students with LD)
Study: 8707471
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (regular education students)
Study: 1848385
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Logiparin) 50 IU anti-Xa per kilo body weight once daily
Study: 6754634
Drug: Labetalol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (300 mg)
Study: 31471834
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) therapy for more than 6 months
Study: 31471834
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) therapy for 6-12 months
Study: 31471834
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) therapy for 12-18 months
Study: 31471834
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) therapy for >24 months
Study: 22978101
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) therapy
Study: 27965485
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 2 to 4°C cold saline irrigated during 5 minutes using EndoVac
Study: 27965485
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of room temperature saline irrigated during 5 minutes using EndoVac
Study: 25214768
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (300 mg gabapentin)
Study: 25214768
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug (300 mg gabapentin)
Study: 17389704
Drug: MMI 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMI 30 mg/d
Study: 17389704
Drug: PTU 300
Normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PTU 300 mg/d
Study: 17389704
Drug: MMI 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMI 15 mg/d
Study: 12789956
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B Kids' Power Toothbrush (D10) for 2 months
Study: 12789956
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B Kids' Power Toothbrush (D10)
Study: 8543722
Drug: Psychodynamic-interpersonal (PI)
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychodynamic-interpersonal (PI) therapy
Study: 8543722
Drug: Cognitive-behavioral (CB)
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral (CB) therapy
Study: 7617806
Drug: Moclobemide (300‐600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (300‐600 mg daily)
Study: 7617806
Drug: Fluoxetine (20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20‐40 mg daily)
Study: 7617806
Drug: Moclobemide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (600 mg daily after doubling dosage for non-responders)
Study: 2571689
Drug: Intracerebroventricular bethanechol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracerebroventricular bethanechol chloride infusion
Study: 19030908
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk (f-milk) without supplements
Study: 11101198
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg mibefradil per day
Study: 11101198
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg mibefradil per day
Study: 11101198
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg mibefradil per day
Study: 8992903
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg IV 30 min before anaesthesia
Study: 1303408
Drug: Conventional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional management and 4 sessions of hyperbaric oxygen therapy
Study: 29898848
Drug: Apixaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (5 mg bid or 2.5 mg bid if combined with antiplatelet therapy)
Study: 29898848
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC Group) including VKA therapy or antiplatelet therapy (single or dual)
Study: 19514478
Drug: Cages (titanium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cages (titanium interbody implants)
Study: 9431711
Drug: Topical 3%
Normalized name: sulfur topical 3% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 3% diclofenac in 2.5% hyaluronic acid gel
Study: 9431711
Drug: Gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing 2.5% hyaluronic acid alone
Study: 29111905
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day CoQ10 supplements
Study: 25980298
Drug: Rituximab in
Normalized name: rituximab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab in combination with methotrexate
Study: 22817868
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of inhaled Salvinorin A
Study: 22817868
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of inhaled Salvinorin A
Study: 22817868
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg of inhaled Salvinorin A (control)
Study: 18832343
Drug: Tolterodine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine (4 mg/d)
Study: 18832343
Drug: Darifenacin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin (15 mg/d)
Study: 12810503
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX‐A) treatment (50 U per axilla)
Study: 12810503
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of life parameters and satisfaction after BTX‐A treatments
Study: 8780660
Drug: 1-unit donation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-unit donation (206 +/- 10 mL)
Study: 8780660
Drug: 2-unit donation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-unit donation (414 +/- 21 mL)
Study: 28624340
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg every 6 months)
Study: 18308653
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg weekly)
Study: 17485150
Drug: recombinant subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant subunit gp350 Epstein-Barr virus vaccine
Study: 11566144
Drug: Opioid blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid blockade with naltrexone (single oral dose)
Study: 9861567
Drug: Amikacin single
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin single daily dosage (20 mg/kg)
Study: 9861567
Drug: Amikacin twice
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin twice daily dosage (20 mg/kg)
Study: 7946862
Drug: Midazolam (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.06 mg kg‐1)
Study: 7946862
Drug: Propofol (2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.2 mg kg‐1 h‐1)
Study: 7946862
Drug: No sedative
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sedative drug (group ND)
Study: 29446174
Drug: Family-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based treatment for bulimia nervosa (FBT-BN)
Study: 29446174
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for adolescents (CBT-A)
Study: 25028357
Drug: IVB (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVB (1.25 mg)
Study: 17087779
Drug: betaine 100
Normalized name: betaine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: betaine 100 mg kg(‐1) day(‐1)
Study: 11878729
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg plus Ondansetron 4 mg
Study: 10195517
Drug: Dextromethorphan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 0.5 mg/kg p.o. 1 hour before surgery
Study: 10195517
Drug: Dextromethorphan 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 1.0 mg/kg p.o. 1 hour before surgery
Study: 2323832
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of birch pollen
Study: 2323832
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of birch pollen (about half the effective dose)
Study: 6985760
Drug: Intermittent sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent sequential pneumatic compression (six chambers) at pressures of 35, 30, and 20 mm Hg for 12 seconds
Study: 6985760
Drug: Sequential compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential compression device
Study: 6985760
Drug: Small-dose subcutaneous
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-dose subcutaneous heparin
Study: 12593177
Drug: Inhaled steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroids
Study: 15540912
Drug: Ceftriaxone, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone, 1 g given twice a day until occurrence of meningitis or at least 5 days after trauma
Study: 15540912
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antibiotic medication)
Study: 9041304
Drug: 1500 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg/kg RSVIG
Study: 8174569
Drug: Once-daily dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosage of 60 mg isosorbide-5-mononitrate
Study: 8174569
Drug: Twice-daily dosage
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dosage of 60 mg isosorbide-5-mononitrate
Study: 3148071
Drug: Oral betaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral betaine, 3 g b.i.d
Study: 28654365
Drug: Protocol-assigned endocrine
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protocol-assigned endocrine therapy
Study: 17598141
Drug: Self-management therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management therapy (n = 51)
Study: 17598141
Drug: Active-control therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active-control therapy (n = 50)
Study: 9436336
Drug: Senna (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna (0.4 mL daily)
Study: 9436336
Drug: Lactulose (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (15 mL daily)
Study: 2520620
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine twice daily (b.d.)
Study: 2520620
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine four times daily (q.d.s.)
Study: 27798417
Drug: Other Angiotensin-converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other Angiotensin-converting enzyme inhibitors
Study: 23933232
Drug: Capsaicin 8%
Normalized name: CAPSAICIN 8% PATCH KIT,4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin 8% patch application (all sites)
Study: 16886330
Drug: Antiparasitic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiparasitic treatment with metronidazole
Study: 8471832
Drug: Pindolol 10
Normalized name: pindolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 10 mg
Study: 29716637
Drug: Ketamine (subdissociative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (subdissociative dose)
Study: 25037206
Drug: Naltrexone 50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50-100 mg/d (flexible dosing)
Study: 22700860
Drug: Prednisone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (1.5 mg/kg/day for 2 weeks followed by 0.75 mg/kg/day for 2 weeks)